Genprex’s Oncoprex included in lung cancer therapy

Genprex’s (GNPX) research collaborators at a major cancer research center in Houston, Texas have published a new study which used the company’s non-viral Oncoprex Delivery System in KRAS/STK11 double mutant anti-PD1 resistant metastatic NSCLC xenografts in humanized mouse models. The Oncoprex Delivery System is a novel non-viral approach utilizing lipid nanoparticles to deliver tumor suppressor genes that have been deleted during the course of cancer development. In the published study, humanized mice were treated with NPRL2 gene therapy, immunotherapy pembrolizumab or the combination. A dramatic antitumor effect was mediated by NPRL2 treatment alone, whereas pembrolizumab alone was ineffective, and the combination added little to NPRL2 treatment alone.